Clinical trials: Oligodendroglioma of Brain
Central Nervous System Cancer, Brain Metastases
Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1
Adult patients with primary or secondary central nervous system malignancies will be invited to undergo a baseline [C-11]-CS1P1 PET scan and a follow-up scan within 24 months of the baseline scan (preferably within 6-months…
- Trial name
- NCT07462507
- Testing
- [C-11]-CS1P1, Brain MRI
- Where
- United States
- Volunteers
- 104 people
- Sponsor
- Washington University School of Medicine
Brain Tumor
Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors
The purpose of this study is to test any good and bad effects of a study drug called abemaciclib (LY2835219) in patients with recurrent brain tumors.
- Trial name
- NCT03220646
- Testing
- abemaciclib
- Where
- 8 sites in United States
- Volunteers
- 64 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Brain and Central Nervous System Tumors
Temozolomide in Treating Patients With Recurrent Malignant Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of temozolomide in treating patients who have recurrent…
- Trial name
- NCT00004113
- Testing
- temozolomide
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Glioblastoma Multiforme, Anaplastic Astrocytoma
Study of a Retroviral Replicating Vector Given Intravenously to Patients Undergoing Surgery for Recurrent Brain Tumor
This is a multicenter study evaluating the safety and tolerability of Toca 511 administered intravenously to patients with recurrent or progressive Grade III or Grade IV Gliomas who have elected to undergo surgical removal of…
- Conditions
- Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma
- Trial name
- NCT01985256
- Testing
- Toca 511, Toca FC
- Where
- 6 sites in United States
- Volunteers
- 17 people
- Sponsor
- Tocagen Inc.
Brain and Central Nervous System Tumors
Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma
RATIONALE: Erlotinib and sirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I/II trial is studying the side effects and best dose of erlotinib when given…
- Trial name
- NCT00509431
- Testing
- Erlotinib + Sirolimus
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Brain and Central Nervous System Tumors
Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00005951
- Testing
- irinotecan hydrochloride, temozolomide
- Where
- United States
- Sponsor
- Duke University
Brain and Central Nervous System Tumors
Cellular Adoptive Immunotherapy Using Genetically Modified T-Lymphocytes in Treating Patients With Recurrent or Refractory High-Grade Malignant Glioma
RATIONALE: Cellular adoptive immunotherapy may stimulate the immune system in different ways and stop cancer cells from growing.
- Trial name
- NCT00730613
- Testing
- therapeutic autologous lymphocytes, gene expression analysis, laboratory biomarker analysis
- Volunteers
- 3 people
- Sponsor
- City of Hope Medical Center
Brain and Central Nervous System Tumors
Irinotecan Followed by Radiation Therapy and Temozolomide in Treating Children With Newly Diagnosed Brain Tumor
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00004068
- Testing
- irinotecan hydrochloride, temozolomide, conventional surgery
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- St. Jude Children's Research Hospital
Childhood Cerebral Anaplastic Astrocytoma, Childhood Oligodendroglioma
Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma
This phase II trial is studying how well giving bevacizumab together with irinotecan works in treating young patients with recurrent, progressive, or refractory glioma, medulloblastoma, ependymoma, or low grade glioma.
- Conditions
- Childhood Cerebral Anaplastic Astrocytoma, Childhood Oligodendroglioma, Childhood Spinal Cord Neoplasm, Recurrent Childhood Brain Stem Glioma
- Trial name
- NCT00381797
- Testing
- Bevacizumab, Fludeoxyglucose F-18, Irinotecan Hydrochloride
- Where
- 11 sites in United States
- Volunteers
- 97 people
- Sponsor
- National Cancer Institute (NCI)
Anaplastic Astrocytoma, Anaplastic Oligodendroglioma
Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms
OBJECTIVES: I. Assess the clinical response of patients with refractory or recurrent brain neoplasms treated with carmustine, streptozocin, and mercaptopurine.
- Conditions
- Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Mixed Gliomas, Glioblastoma Multiforme
- Trial name
- NCT00004688
- Testing
- carmustine, mercaptopurine, streptozocin
- Volunteers
- 35 people
- Sponsor
- Emory University
Brain and Central Nervous System Tumors
Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00498927
- Testing
- temozolomide, protein expression analysis, reverse transcriptase-polymerase chain reaction
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Brain and Central Nervous System Tumors
Arsenic Trioxide, Temozolomide, and Radiation Therapy in Treating Patients With Malignant Glioma That Has Been Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00275067
- Testing
- arsenic trioxide, temozolomide, radiation therapy
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Northwestern University
Brain and Central Nervous System Tumors, Lymphoma
Gene Therapy and Chemotherapy in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
RATIONALE: Gene therapy may improve the body's ability to fight cancer or make the cancer more sensitive to chemotherapy. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or…
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
- Trial name
- NCT00003567
- Testing
- filgrastim, sargramostim, therapeutic autologous lymphocytes
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Case Comprehensive Cancer Center
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Temozolomide Plus Peripheral Stem Cell Transplantation in Treating Children With Newly Diagnosed Malignant Glioma or Recurrent CNS or Other Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Head and Neck Cancer, Kidney Cancer
- Trial name
- NCT00005952
- Testing
- filgrastim, temozolomide, peripheral blood stem cell transplantation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Duke University
Glioblastoma, Astrocytoma
Efficacy of Protracted Temozolomide in Patients With Progressive High Grade Glioma
The purpose of this study is to evaluate the efficacy of temozolomide on a protracted schedule, after standard 5-day temozolomide regimen in patients with recurrent or progressive high grade glioma.
- Conditions
- Glioblastoma, Astrocytoma, Oligodendroglioma, Brain Tumor, Recurrent
- Trial name
- NCT00575887
- Testing
- Temozolomide
- Where
- Turkey (Türkiye)
- Volunteers
- 25 people
- Sponsor
- Marmara University
Brain Cancer
Safety Study of Afatinib for Brain Cancer
The purpose of this study is to try to determine the maximum safe dose of afatinib that can be administered to people with brain cancer.
- Trial name
- NCT02423525
- Testing
- Afatinib
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Santosh Kesari
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma
Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme
This partially randomized phase I/II trial studies the side effects and the best dose of anti-endoglin monoclonal antibody TRC105 when given together with bevacizumab and to see how well they work in treating patients with…
- Conditions
- Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma
- Trial name
- NCT01648348
- Testing
- Anti-Endoglin Chimeric Monoclonal Antibody TRC105, Bevacizumab, Laboratory Biomarker Analysis
- Where
- 308 sites in United States
- Volunteers
- 116 people
- Sponsor
- National Cancer Institute (NCI)
Brain and Central Nervous System Tumors
Imatinib Mesylate, Vatalanib, and Hydroxyurea in Treating Patients With Recurrent or Relapsed Malignant Glioma
RATIONALE: Imatinib mesylate, vatalanib, and hydroxyurea may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Trial name
- NCT00387933
- Testing
- hydroxyurea, imatinib mesylate, vatalanib
- Where
- United States
- Volunteers
- 37 people
- Sponsor
- Duke University
Central Nervous System Neoplasms, Glioblastoma
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
The primary objective of this Phase 1, open-label, dose-escalation, and exploratory study is to evaluate the safety and tolerability profile (establish the maximum-tolerated dose) and evaluate the occurrence of dose-limiting…
- Conditions
- Central Nervous System Neoplasms, Glioblastoma, Gliosarcoma, Adult, Anaplastic Oligodendroglioma
- Trial name
- NCT04541082
- Testing
- ONC206
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- Jazz Pharmaceuticals
Adult Central Nervous System Germ Cell Tumor, Adult Malignant Meningioma
Stereotactic Radiosurgery in Treating Patients With Brain Tumors
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. PURPOSE: Phase I trial to study the effectiveness of stereotactic radiosurgery in treating patients who have brain tumors.
- Conditions
- Adult Central Nervous System Germ Cell Tumor, Adult Malignant Meningioma, Adult Medulloblastoma, Adult Noninfiltrating Astrocytoma
- Trial name
- NCT00019578
- Testing
- Sterotactic radiosurgery
- Where
- United States
- Sponsor
- National Institutes of Health Clinical Center (CC)